ClinicalTrials.gg
DrugRead study by study

Remibrutinib clinical trials

Also written LOU064.

studies test it
35
open now
12
in phase 3
22
first study started
2016
ClinicalTrials.gov finds 41 studies for remibrutinib. How that becomes 35 here

Every study that search finds has been read, to see whether and how it gives remibrutinib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 41Found by its intervention search · See all 41 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 33 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. +1Give it under a name that search misses: a biosimilar’s code or a misspelling
  3. 42Give remibrutinib to participants
  4. −7Observe patients on it, or give it outside a trial
  5. 35Test it: the count on this site

Get an email when these change. Save the remibrutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
30 Sept 2025 · RHAPSIDO · NDA 218436 (FDA, Drugs@FDA)
European Union
23 Apr 2026 · Rhapsido · EMEA/H/C/006313 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Remibrutinib
24
LOU064 (blinded)
3
Remibrutinib (Open Label)
3
Remibrutinib Dose A
2
Remibrutinib Dose B
2

Development codes

LOU064
21

Studies by the year they started

34 studies that test it; most in 2025 (8); 1 more planned to start later

Studies that test remibrutinib, by start year
YearStudies
20161
20195
20214
20224
20234
20258
20268

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
9
Phase 3
22

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 34 · Other 1

Novartis Pharmaceuticals (34) · Moein Amin (1)

Often tested with

Tested in the same studies.

Iscalimab (1) · LYS-006 (1) · Arumakimig (1) · Ianalumab (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 6, 4 in phase 3

Studies that test remibrutinib, phase 3 first.

Studies

Open first, then newest update. How each study uses remibrutinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 35

See all 35 studies that test remibrutinib →

Behind its US label · 2 — the studies the FDA label of RHAPSIDO describes

From the Clinical Studies section of RHAPSIDO (2026-03), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 34 — no other medicine in its arm

Showing 20 of 34. See all 34 →

Tested in a combination · 1 — another drug in the study is under test too
Observed · 7 — patients on it are followed, or it is given outside a trial

Codes

What other systems call remibrutinib · ClinicalTrials.gg INT001907

  • MeSH (NLM) C000722911remibrutinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) I7MVZ8HDNUREMIBRUTINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q123499462remibrutinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C175851RemibrutinibOne source FDA
  • DrugBank DB16852One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion